Managing one’s weight may be a bit difficult, especially when it comes to consistency. However, did you know that continuous glucose monitoring (CGM) technology can help? CGM is usually used by individuals with diabetes to help manage and monitor their blood sugar. However, the demand for personalized nutrition has seen continuous glucose monitoring devices being used outside the diabetes space.
For instance, companies such as NutriSense promote their CGM product as an overall health solution for everything, including weight loss. NutriSense is focused on improving metabolic health. The company leverages its advanced continuous glucose monitoring technology to personalize individual nutrition.
NutriSense cofounder and COO Dan Zavorotny stated that there was an increasing awareness about glucose as an important vital sign, noting that continuous glucose monitoring technologies were the best way to gather data on glucose levels as consumers took more responsibility for their health. Zavorotny added that these wearable devices also empowered users to learn more about themselves in interesting and new ways.
In addition, he highlighted that consumers were more open to these wearable devices after becoming comfortable with the use of products such as the Apple Watch and Fitbit. These wearable CGM devices are usually fastened to an individual’s arm, helping monitor levels of blood glucose at all times. The data collected by the device is then sent to an application which is integrated with factors which affect levels of blood glucose, including exercise, diet and sleep.
Glucose is the primary type of sugar in the blood. It fuels everything in an individual’s body, from their lungs to the brain, which is said to be the largest consumer of glucose. Experts believe that the brain uses almost half of the glucose in the body in order to function.
The use of this technology, such as the patented sugarBEAT device made by Nemaura Medical Inc. (NASDAQ: NMRD), makes this a far more efficient way to monitor blood sugar levels, especially when compared to the conventional method that involves pricking a patient’s finger and drawing blood to monitor their glucose levels. Higher than normal glucose levels are known to cause chronic conditions like diabetes, as well as lead to the brain and body’s aging and weight gain.
NutriSense’s director of nutrition and cofounder Kara Collier stated that higher glucose levels in an individual’s blood could cause weight gain by activating the body’s insulin response, which would cause insulin to be produced by the pancreas and prompt the body to store energy in the form of fat. Insulin is a hormone that regulates the amount of glucose in an individual’s blood.
NOTE TO INVESTORS: The latest news and updates relating to Nemaura Medical Inc. (NASDAQ: NMRD) are available in the company’s newsroom at https://ibn.fm/NMRD
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork.